Van ECK Associates Corp Sells 224,170 Shares of Elanco Animal Health Incorporated $ELAN

Posted by Stanley Muller on Aug 31st, 2026

Van ECK Associates Corp decreased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 24.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 707,194 shares of the company’s stock after selling 224,170 shares during the quarter. Van ECK Associates Corp owned about 0.14% of Elanco Animal Health worth $17,404,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Parallel Advisors LLC increased its holdings in shares of Elanco Animal Health by 5.9% in the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after buying an additional 392 shares during the last quarter. Sapient Capital LLC grew its position in Elanco Animal Health by 0.3% in the second quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock worth $3,164,000 after acquiring an additional 420 shares in the last quarter. Lazard Asset Management LLC increased its stake in Elanco Animal Health by 0.6% during the fourth quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after acquiring an additional 425 shares during the last quarter. Northwestern Mutual Investment Management Company LLC raised its position in Elanco Animal Health by 0.4% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock valued at $2,516,000 after purchasing an additional 428 shares during the period. Finally, Meeder Advisory Services Inc. raised its position in Elanco Animal Health by 4.8% during the fourth quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock valued at $254,000 after purchasing an additional 510 shares during the period. Institutional investors own 97.48% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Citigroup boosted their target price on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. raised their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Morgan Stanley lifted their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 22nd. KeyCorp boosted their price objective on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Finally, UBS Group increased their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health currently has an average rating of “Moderate Buy” and a consensus price target of $29.09.

View Our Latest Report on ELAN

Insider Transactions at Elanco Animal Health

In related news, Director Paul Herendeen bought 10,000 shares of the company’s stock in a transaction on Friday, August 7th. The shares were acquired at an average cost of $23.68 per share, for a total transaction of $236,800.00. Following the purchase, the director directly owned 111,687 shares of the company’s stock, valued at approximately $2,644,748.16. The trade was a 9.83% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michael J. Harrington bought 5,000 shares of Elanco Animal Health stock in a transaction dated Wednesday, August 12th. The shares were bought at an average cost of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the transaction, the director owned 131,451 shares of the company’s stock, valued at approximately $2,868,260.82. This trade represents a 3.95% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 63,198 shares of company stock valued at $1,473,109. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Price Performance

Shares of ELAN stock opened at $24.16 on Monday. Elanco Animal Health Incorporated has a 52-week low of $17.11 and a 52-week high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The firm has a market capitalization of $12.07 billion, a P/E ratio of -58.93, a P/E/G ratio of 1.44 and a beta of 1.67. The stock has a 50 day moving average price of $24.62 and a 200 day moving average price of $24.00.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. During the same quarter in the previous year, the business earned $0.26 EPS. Elanco Animal Health’s revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, sell-side analysts predict that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Elanco Animal Health Company Profile

(Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.